Gilteritinib plus other IDH medicine for relapsed AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 study tests how well gilteritinib works when combined with either ivosidenib or enasidenib in adults with relapsed or refractory acute myeloid leukemia (AML). It targets specific genetic changes in the leukemia and may help shrink or control the cancer when standard options haven’t worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to follow the study visit schedule and rules
- Have relapsed or refractory AML that has specific gene changes: IDH1 or IDH2 plus FLT3 (or another FLT3 change that gilteritinib can target)
- Have recent lab proof of these gene changes from a bone marrow or blood test done within the last 30 days
- Be able to safely take study pills (for example, no swallowing or stomach absorption problems for oral medicines)
- Have certain heart and organ health measures that are “good enough” for treatment (kidney, liver, and heart rhythm/heart pumping limits)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies ivosidenib together with azacitidine in people newly diagnosed with AML that has an IDH1 R132 gene mutation. It’s meant for patients who are not able to safely receive the strongest (intensive) chemotherapy, with the goal of improving control of the leukemia.
This trial tests two maintenance drugs (gilteritini and sorafenib) for people with FLT3-ITD positive AML after a stem cell transplant. It compares which drug better prevents relapse using a sensitive test for minimal residual disease (MRD).
This trial tests a combination of three targeted drugs for people with a specific type of AML that has an IDH1 mutation. The goal is to see if the combination helps control the leukemia and if continuing with just ivosidenib can keep it in remission.
This trial tests if adding the targeted drug gilteritinib to standard chemotherapy improves outcomes for adults with a specific type of AML (FLT3-ITD+). It's for newly diagnosed patients who can tolerate intensive treatment.
This trial tests a new combination of chemotherapy (FLAI) and a targeted drug (Gilteritinib) for adults with acute myeloid leukemia (AML) that has a specific genetic change called FLT3. It aims to see if the combo works better than standard treatment.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.